Validation of Pre-Clinical Nano-Based Analgesics in Cells From Dorsal Root Ganglia
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Viability assays
研究概览
简要总结
This study investigates the pre-clinical nano-based analgesics in cells from human dorsal root ganglia (clusters of neurons). Collecting these neurons may help future research related to safe and effective pain treatment.
详细描述
PRIMARY OBJECTIVE:
I. To identify translational mechanisms and therapeutics for neuropathic pain, a type of chronic pain that can arise due to injured nerves.
OUTLINE:
Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •--All patients undergoing surgery to resect spinal tumors
排除标准
- 未提供
研究组 & 干预措施
Basic science (dorsal root ganglia collection)
Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
干预措施: Biospecimen Collection (Procedure)
结局指标
主要结局
Viability assays
时间窗: 3 years
The Viability outcome measure will be expressed using percentage units. This will be calculated as the percentage of cells in culture that are able to exclude a cell permeable dye (Ethidium homodimer) from their nucleus. Entry of this dye into the nucleus and fluorescent binding to nuclear DNA is indicative of a dead/dying cell. Cultured cells that have undergone control or active nanoemulsion treatment in vitro will be loaded with a fluorescent calcium-sensitive dye and continuously monitored while excitation is evoked with a panel of ion channel agonists. The fold-change in intracellular calcium concentration over baseline in response to such excitation is the outcome measure.
Functional assays
时间窗: 3 years
Neurons will be isolated from fresh tissues and used in assays in which cells are stimulated with pronociceptive chemicals (e.g. agonists for ion channels, pattern recognition receptors, G protein-coupled receptors). Cell activity will be quantified as appropriate (e.g. calcium mobilization). Experimental endpoints will be analyzed using a between-subjects designs to assess differences between patients with and without nerve compression. ANOVA will be performed in a 2 (neuropathic pain vs. control) x 4 (3 treatments vs. control) design. Bonferroni posthoc tests will be applied when significant interactions are found. Age, sex, ethnicity, cancer diagnosis, drug treatments, and history of chronic pain will be included as covariates.
次要结局
未报告次要终点
